SEC Tracker
Get the app

CVRx CVRX

CVRx reported a $14.16 million net loss for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $13.83 million for the three months ended Sep 30, 2026.
  2. Net loss: $14.16 million for the three months ended Sep 30, 2026.
  3. Diluted EPS: -$0.52 for the three months ended Sep 30, 2026.
  4. Cash and equivalents: $58.75 million at Sep 30, 2026.

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when CVRx files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Venus Concept VERO
  2. LENSAR LNSR public float $113M, Jun 30, 2025
  3. TriSalus Life Sciences TLSI public float $112M, Jun 30, 2025
  4. KORU Medical Systems KRMD public float $119M, Jun 30, 2025
  5. InfuSystem Holdings INFU public float $122M, Jun 30, 2025